Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.60 |
| ▸ | PLAU | P00749 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277584 | 0.85 | ALDH1A1 (0.70) | MAPTKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL10560904 | 0.84 | ALDH1A1 (0.75) | MAPTKDM4EALDH1A1GFERGAA | |
| SCHEMBL1127878 | 0.82 | KDM4E (1.00) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL1841753 | 0.82 | P2RX1 (0.54) | MAPTKDM4EALDH1A1KLKB1PLAU | |
| Hydrochloric Acid SCHEMBL21381943 | 0.81 | KDM4E (0.96) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL10705838 | 0.81 | KDM4E (0.70) | MAPTKDM4EALDH1A1GFERGAA | |
| SCHEMBL3814303 | 0.81 | P2RX1 (0.53) | MAPTKDM4EALDH1A1KLKB1PLAU | |
| SCHEMBL1303113 | 0.80 | ALDH1A1 (1.00) | MAPTKDM4EALDH1A1GFERGAA | |
| SCHEMBL4880939 | 0.79 | CA1 (0.52) | MAPTKDM4EALDH1A1GFERKLKB1 | |
| SCHEMBL4349861 | 0.79 | KDM4E (0.68) | MAPTKDM4EALDH1A1GFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024460-A | Diboropyrrole salicylhydrazone fluorescent dye and preparation method thereof | 安徽中天新材料科技股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-117024460-A | Diboropyrrole salicylhydrazone fluorescent dye and preparation method thereof | 安徽中天新材料科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| CN-1441800-A | β3Adrenergic agonists | LILLY CO ELI (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| US-4179439-A | Rifamycins and method for their preparation | INTREPRINDEREA DE ANTIBIOTICE IASI (RO) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | MAPT 1813/4885KDM4E 3395/4885ALDH1A1 1255/4885 |
| US-20040242633-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | MAPT 2096/4885KDM4E 3557/4885ALDH1A1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.